Literature DB >> 2527543

The influence of cilazapril on indices of autonomic function in normotensives and hypertensives.

H L Elliott1, A A Ajayi, J L Reid.   

Abstract

1. In two single dose studies, acute blood pressure reduction with cilazapril was not associated with any significant change in supine or erect heart rate in either normotensives or hypertensives. 2. To investigate the lack of reflex cardioacceleration, a series of autonomic function tests was undertaken when there was maximum ACE inhibition, maximum evidence of angiotensin II withdrawal and the lowest blood pressure. 3. There was no evidence that cilazapril had any significant impact on indices of sympathetic nervous activity or the integrity of baroreflex mechanisms. 4. The results for the bradycardic response to apnoeic facial immersion, suggested enhanced parasympathetic activity, consistent with the withdrawal of the vagolytic actions of angiotensin II. 5. These results suggest that the absence of a heart rate response to ACE inhibition is not related to a profound sympatho-inhibitory effect or an impairment of baroreflex function. While there is some evidence of enhanced cardiac parasympathetic tone it seems unlikely that this is the sole explanation for the lack of cardioacceleration.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2527543      PMCID: PMC1379762          DOI: 10.1111/j.1365-2125.1989.tb03496.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Reflex heart rate control in man.

Authors:  D F Leon; J A Shaver; J J Leonard
Journal:  Am Heart J       Date:  1970-12       Impact factor: 4.749

2.  Vagal and sympathetic contributions to the heart rate at rest and during isometric and dynamic exercise in young healthy men.

Authors:  G Nyberg
Journal:  J Cardiovasc Pharmacol       Date:  1981 Nov-Dec       Impact factor: 3.105

Review 3.  Adrenergic facilitation by angiotensin: does it serve a physiological function?

Authors:  B G Zimmerman
Journal:  Clin Sci (Lond)       Date:  1981-04       Impact factor: 6.124

4.  A simple test of cardiac function based upon the heart rate changes induced by the Valsalva maneuver.

Authors:  A B Levin
Journal:  Am J Cardiol       Date:  1966-07       Impact factor: 2.778

5.  Acute and chronic effects of the converting enzyme inhibitors enalapril and lisinopril on reflex control of heart rate in normotensive man.

Authors:  A A Ajayi; B C Campbell; C A Howie; J L Reid
Journal:  J Hypertens       Date:  1985-02       Impact factor: 4.844

6.  Cardiac denervation in diabetes.

Authors:  T Wheeler; P J Watkins
Journal:  Br Med J       Date:  1973-12-08

7.  Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521.

Authors:  J A Millar; F H Derkx; K McLean; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

8.  Autonomic control of the immediate heart rate response to lying down.

Authors:  F Bellavere; D J Ewing
Journal:  Clin Sci (Lond)       Date:  1982-01       Impact factor: 6.124

9.  The effect of captopril on the reflex control heart rate: possible mechanisms.

Authors:  A A Ajayi; B C Campbell; P A Meredith; A W Kelman; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1985-07       Impact factor: 4.335

10.  Evidence of parasympathetic activity of the angiotensin converting enzyme inhibitor, captopril, in normotensive man.

Authors:  B C Campbell; A Sturani; J L Reid
Journal:  Clin Sci (Lond)       Date:  1985-01       Impact factor: 6.124

View more
  2 in total

Review 1.  Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease.

Authors:  F Deget; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

Review 2.  Clinical pharmacology of cilazapril.

Authors:  C H Kleinbloesem; P van Brummelen; R J Francis; U W Wiegand
Journal:  Drugs       Date:  1991       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.